Table 2.
Patients characteristics of DDGP and SMILE groups
| Characteristic | Number of patients (%) | P value | |
|---|---|---|---|
| DDGP (N = 31) | SMILE (N = 23) | ||
| Age, years | |||
| Median | 39 | 37 | 0.123 |
| Range | 21–65 | 15–61 | |
| Sex | |||
| Male | 22 (71.0%) | 16 (69.6%) | 0.911 |
| Female | 9 (29.0%) | 7 (30.4%) | |
| Disease status | |||
| Relapse | 16 (51.6%) | 15 (65.2%) | 0.317 |
| Refractory | 15 (48.4%) | 8 (34.8%) | |
| Ann Arbor stage | |||
| Ⅰ/Ⅱ | 11 (35.5%) | 5 (21.7%) | 0.274 |
| Ⅲ/Ⅳ | 20 (64.5%) | 18 (78.3%) | |
| B symptoms present | 10 (32.3%) | 10 (43.5%) | 0.399 |
| Elevated β2‐microglobulin | 8 (25.8%) | 8 (34.8%) | 0.475 |
| Elevated LDH | 11 (35.5%) | 13 (56.5%) | 0.124 |
| Pretreatment EBV‐DNA | |||
| Positive | 15 (48.4%) | 9 (39.1%) | 0.498 |
| Negative | 16 (51.6%) | 14 (60.9%) | |
| IPI | |||
| 0–2 | 13 (41.9%) | 8 (34.8%) | 0.594 |
| 3–5 | 18 (58.1%) | 15 (65.2%) | |
| PINK‐E | |||
| 0–2 | 14 (45.2%) | 13 (56.5%) | 0.409 |
| 3–5 | 17 (54.8%) | 10 (43.5%) | |
| ECOG PS | |||
| 0–1 | 19 (61.3%) | 9 (39.1%) | 0.107 |
| 2–4 | 12 (38.7%) | 14 (60.9%) | |
DDGP, cisplatin, dexamethasone, gemcitabine, and pegaspargase; EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PINK‐E, prognostic index of natural killer lymphoma with data for EBV‐DNA; SMILE, methotrexate, dexamethasone, ifosfamide, L‐asparaginase, and etoposide.